Insulet Raises Revenue Outlook After Quarterly Beat
Insulet raised its 2026 revenue forecast following strong quarterly results. Demand for Omnipod 5 pumps drove revenue to $761.7 million, beating expectations.
Xurve View
Insights:
Xurve View
Insulet raised its 2026 revenue growth forecast to a range of 21% to 23% following a first-quarter earnings beat on Wednesday. The medical device maker previously projected growth between 20% and 22% as demand for its tubeless insulin pumps accelerates. This revision signals successful capture of the expanding diabetes technology market.
